310 related articles for article (PubMed ID: 36859811)
1. Drug Discovery Perspectives of Antisense Oligonucleotides.
Kim Y
Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
[TBL] [Abstract][Full Text] [Related]
2. Antisense technology: an overview and prospectus.
Crooke ST; Baker BF; Crooke RM; Liang XH
Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
[TBL] [Abstract][Full Text] [Related]
3. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.
Dhuri K; Bechtold C; Quijano E; Pham H; Gupta A; Vikram A; Bahal R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604776
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks.
Nakamura A; Ali SA; Kapoor M
Bone; 2020 Sep; 138():115461. PubMed ID: 32485363
[TBL] [Abstract][Full Text] [Related]
5. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Sang A; Zhuo S; Bochanis A; Manautou JE; Bahal R; Zhong XB; Rasmussen TP
BioDrugs; 2024 Jun; ():. PubMed ID: 38914784
[TBL] [Abstract][Full Text] [Related]
7. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
[TBL] [Abstract][Full Text] [Related]
8. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
9. Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs.
Liang XH; Nichols JG; Sun H; Crooke ST
Nucleic Acids Res; 2018 Jan; 46(1):293-313. PubMed ID: 29165591
[TBL] [Abstract][Full Text] [Related]
10. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines.
Linnane E; Davey P; Zhang P; Puri S; Edbrooke M; Chiarparin E; Revenko AS; Macleod AR; Norman JC; Ross SJ
Nucleic Acids Res; 2019 May; 47(9):4375-4392. PubMed ID: 30927008
[TBL] [Abstract][Full Text] [Related]
11. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
12. A single-cell map of antisense oligonucleotide activity in the brain.
Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
14. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
Quemener AM; Centomo ML; Sax SL; Panella R
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
[TBL] [Abstract][Full Text] [Related]
15. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
[TBL] [Abstract][Full Text] [Related]
16. The powerful world of antisense oligonucleotides: From bench to bedside.
Quemener AM; Bachelot L; Forestier A; Donnou-Fournet E; Gilot D; Galibert MD
Wiley Interdiscip Rev RNA; 2020 Sep; 11(5):e1594. PubMed ID: 32233021
[TBL] [Abstract][Full Text] [Related]
17. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
18. Factors Influencing ADME Properties of Therapeutic Antisense Oligonucleotides: Physicochemical Characteristics and Beyond.
Jiang R; Hooshfar S; Rebecca Eno M; Yun C; Sonego Zimmermann E; Shinkyo R
Curr Drug Metab; 2023; 24(7):536-552. PubMed ID: 37076460
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
20. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
